Product Code: GVR-4-68040-087-2
Cell Freezing Media Market Growth & Trends
The global cell freezing media market size is expected to reach USD 291.3 million by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 9.62% from 2023 to 2030, driven by increasing adoption of ready to freezing media, coupled with growing pipeline of biopharmaceuticals leading to a higher demand for these products. In addition, increasing prevalence of chronic disorders, and risen significance of cells therapies in managing them have created traction for effective cell freezing medium.
The growing research and development activities to develop advanced therapies have resulted in increased demand for the cost-effective cryopreservation medium. The ability of ready to use media to reduce the ice crystals formation while cryopreserving viable cells eventually led to its increasing adoption among research community. Furthermore, the increased popularity of biopharmaceuticals due to improved safety and efficacy has cascaded huge investments from manufacturers to develop advanced biopharmaceuticals for life-threatening disorders.
The rapid research and development of COVID-19 vaccine and its continuous commercial production activities has also positively impacted as well as encouraged the biologics-based research activities and eventually boosted the market growth. The increasing market demand, growing competition among players and various application by end users has also attributed to advancements in formulations of cell freezing media and are now even available as per custom requirements. For instance, the Sigma Aldrich brand of Merck KGaA offers freezing media solutions for stem cells application while providing optimal recovery and cells survival.
Rapid advancements in cellular therapy research and growing adoption of cell therapies in various disorders have created a robust demand in the global market. Cell freezing media has a very important role in maintaining functionality of cells during the thawing and freezing process, which is vital for cell therapies applications. In addition, various strategies undertaken by market participants to bolster applications of cellular therapies in managing chronic disorders are projected to accelerate market expansion. For instance, in September 2022, Scribe Therapeutics and Sanofi announced partnership to commercialize CRISPR based therapies for cancer.
Cell Freezing Media Market Report Highlights
- The DMSO (dimethyl sulfoxide) segment dominated the market in 2022 with a revenue share of 51.46% and is attributed to the established gold standard from years of using DMSO in traditional cryopreservation for suspending the metabolic activities of cells
- The stem cells lines segment has the largest application of cell freezing media, whereas cancer cell lines expected to witness fastest growth owing to the increasing clinical success rate of cell and gene therapy products
- Across end use segment, the pharmaceutical and biotechnology companies segment dominated the market with the revenue share of 42.42% in 2022. The higher revenue growth is attributed to the continuous growth and commercial success of biopharmaceuticals coupled with the expanding portfolio of the major pharmaceutical companies
- North America region dominated the global market in 2022, owing to expanding pipeline for biopharmaceuticals, a large pool of key players, rising demand for cell freezing media, and advanced healthcare infrastructure along with developed economy
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Information Procurement
- 1.2. Information Or Data Analysis
- 1.3. Market Scope & Segment Definition
- 1.4. Market Model
- 1.4.1. Market Study, By Company Market Share
- 1.4.2. Regional Analysis
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing demand for cell-based therapies and regenerative medicine
- 3.2.1.2. Increasing R&D spending by biopharmaceutical and biotechnology companies
- 3.2.1.3. Advancements in cryopreservation techniques and biopreservation technologies
- 3.2.1.4. Increasing prevalence of chronic diseases and genetic disorders
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost associated with cryopreservation and cell freezing media
- 3.2.2.2. Stringent regulatory requirements for cell-based products and cryopreservation systems
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
- 4.1. Cell Freezing Media Market: Product Movement Analysis
- 4.2. DMSO
- 4.2.1. DMSO Market, 2018 - 2030 (USD Million)
- 4.2.2. DMSO With Serum
- 4.2.2.1. DMSO With Serum Market, 2018 - 2030 (USD Million)
- 4.2.3. DMSO Without Serum
- 4.2.3.1. DMSO With Serum Market, 2018 - 2030 (USD Million)
- 4.3. Glycerol
- 4.3.1. Glycerol Market, 2018 - 2030 (USD Million)
- 4.3.2. Glycerol With Serum
- 4.3.2.1. Glycerol With Serum Market, 2018 - 2030 (USD Million)
- 4.3.3. Glycerol Without Serum
- 4.3.3.1. Glycerol With Serum Market, 2018 - 2030 (USD Million)
- 4.4. Others
- 4.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. Cell Freezing Media Market: Application Movement Analysis
- 5.2. Stem Cell Lines
- 5.2.1. Stem Cell Lines Market, 2018 - 2030 (USD Million)
- 5.3. Cancer Cell Lines
- 5.3.1. Cancer Cell Lines Market, 2018 - 2030 (USD Million)
- 5.4. Others
- 5.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
- 6.1. Cell Freezing Media Market: End-Use Movement Analysis
- 6.2. Pharmaceutical & Biotechnology Companies
- 6.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
- 6.3. Academic and Research Institutes
- 6.3.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)
- 6.4. Others
- 6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Cell Freezing Media Market Share By Region, 2022 & 2030
- 7.2. North America
- 7.2.1. SWOT Analysis
- 7.2.2. North America Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.2.3. U.S.
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. U.S. Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.2.4. Canada
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Competitive Scenario
- 7.2.4.4. Canada Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. SWOT Analysis
- 7.3.2. Europe Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. UK Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.4. Germany
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Germany Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.5. France
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. France Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.6. Italy
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Italy Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.7. Spain
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Spain Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.8. Denmark
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Denmark Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.9. Sweden
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Sweden Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.3.10. Norway
- 7.3.10.1. Key Country Dynamics
- 7.3.10.2. Target Disease Prevalence
- 7.3.10.3. Competitive Scenario
- 7.3.10.4. Norway Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. SWOT Analysis
- 7.4.2. Asia Pacific Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Japan Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.4. China
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. China Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.5. India
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. India Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Australia Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Thailand Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.4.8. South Korea
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Target Disease Prevalence
- 7.4.8.3. Competitive Scenario
- 7.4.8.4. South Korea Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. SWOT Analysis
- 7.5.2. Latin America Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.5.3. Brazil
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Brazil Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Mexico Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.5.5. Argentina
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Argentina Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.6. MEA
- 7.6.1. SWOT Analysis
- 7.6.2. MEA Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.6.3. South Africa
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. South Africa Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.6.4. Saudi Arabia
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Saudi Arabia Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.6.5. UAE
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. UAE Cell Freezing Media Market, 2018 - 2030 (USD Million)
- 7.6.6. Kuwait
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Competitive Scenario
- 7.6.6.4. Kuwait Cell Freezing Media Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share Analysis, 2022
- 8.4. Company Profiles/Listing
- 8.4.1. Thermo Fisher Scientific, Inc
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Merck KGaA
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Sartorius AG
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Bio-Life Solutions, Inc.
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Bio-Techne
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. HiMedia Laboratories
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. PromoCell GmbH
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Capricorn Scientific
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Cell Applications, Inc.
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. AMSBIO
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives